Ibandronate Sodium
This sodium salt of ibandronate is a bisphosphonate used to treat osteoporosis in postmenopausal women and bone metastases from breast cancer. It reduces bone resorption by inhibiting osteoclasts, which helps to strengthen bones and reduce fracture risk. Monthly oral tablets or quarterly intravenous infusions are available.
Peso Molecular
359,2300 g/mol
TPSA
142,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCCCCN(C)CCC(O)(P(=O)([O-])O)P(=O)(O)O.O.[Na+]
InChI
InChI=1S/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1
Molecular Formula
C9H24NNaO8P2
HBD / HBA
5 / 9
Ligações Rotacionáveis
9
Átomos Pesados
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This sodium salt of ibandronate is a bisphosphonate used to treat osteoporosis in postmenopausal women and bone metastases from breast cancer. It reduces bone resorption by inhibiting osteoclasts, which helps to strengthen bones and reduce fracture risk. Monthly oral tablets or quarterly intravenous infusions are available.
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Yes, Ibandronate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989569. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23663991. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ibandronate-sodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ibandronate-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ibandronate-sodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ibandronate-sodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ibandronate-sodium"></drugfyi-drug>